# Kunuka (Buddleja coriacea)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/kunuka-buddleja-coriacea
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** South American
**Also Known As:** Buddleja coriacea, Kunuka, Quechua respiratory herb, Andean buddleja, coarse-leaved buddleja

## Overview

Buddleja coriacea leaf extracts contain at least three bioactive compounds—including two uncharacterized isolates (Compound 2 and Compound 3) and a probable dione derivative (Compound 1)—that inhibit the pro-[inflammatory](/ingredients/condition/inflammation) transcription factor NF-κB with IC50 values as low as 0.15–0.16 µM and exhibit antibacterial activity with MIC values of 0.17–0.19 µM, surpassing the reference antibiotic ofloxacin (MIC 27.66 µM) in vitro. The hexane subextract fractions F3 and F4 produced zones of inhibition of 34.03–35.85 mm against bacterial strains, representing the strongest preclinical antibacterial data reported for this species to date.

## Health Benefits

- **[Anti-inflammatory](/ingredients/condition/inflammation) Activity**: Isolated compounds from B. coriacea leaf extracts inhibit NF-κB, a master transcription factor driving inflammatory cytokine production, with Compound 2 achieving an IC50 of 0.15–0.16 µM—significantly more potent than the positive control celastrol at 7.96 µM in the same assay.
- **Antibacterial Properties**: Hexane subextract fractions F3 and F4 demonstrate zones of inhibition of 34.03–35.85 mm and MIC values of 30.01–30.52 µg/mL against tested bacterial strains, outperforming the aqueous extract (p < 0.001) and suggesting potential utility against susceptible pathogens.
- **Respiratory Support (Traditional)**: In Andean Quechua ethnomedicine, kunuka leaf preparations are used to manage respiratory ailments including cough, bronchial congestion, and altitude-related respiratory discomfort, a use consistent with the plant's anti-inflammatory profile but not yet validated in clinical trials.
- **Digestive Support (Traditional)**: Quechua healers prepare kunuka infusions for digestive complaints such as bloating, gastric pain, and intestinal inflammation, likely mediated by the same NF-κB-inhibitory compounds identified in laboratory studies.
- **COX and LOX Enzyme Inhibition (Class-Level Evidence)**: Related Buddleja species contain buddledin A, which inhibits cyclooxygenase (COX IC50 13.7 µM) and 5-lipoxygenase (5-LOX IC50 50.4 µM), enzymes central to eicosanoid-driven inflammation; while not confirmed specifically in B. coriacea, the genus-level pharmacology provides a plausible mechanistic rationale.
- **[Antioxidant](/ingredients/condition/antioxidant) Flavonoid Content (Inferred)**: The Buddleja genus is broadly characterized by the presence of flavonoids such as verbascoside and buddlenoid B, compounds with demonstrated free-energy binding to therapeutic targets (−48.73 to −53.64 kcal/mol in computational models), suggesting antioxidant and cytoprotective potential in B. coriacea pending direct chemical analysis.
- **Low Cytotoxicity Potential**: In the available in vitro fractionation study, the most bioactive fractions (F1, F3, F4) displayed lower cytotoxicity relative to other isolated fractions from the same extract, a preliminary indicator of a potentially favorable therapeutic index that requires formal toxicological characterization.

## Mechanism of Action

The primary characterized mechanism of B. coriacea is inhibition of NF-κB, a transcription factor that, when activated, drives expression of pro-inflammatory genes including TNF-α, IL-1β, IL-6, and COX-2; Compound 2 achieves this with an IC50 of 0.15–0.16 µM and Compound 3 at 0.33–0.36 µM, both significantly more potent than the standard inhibitor celastrol (IC50 7.96 µM) under the same experimental conditions. The antibacterial activity of the hexane-soluble isolates, with MIC values of 0.17–0.36 µM, likely reflects disruption of bacterial membrane integrity or inhibition of essential bacterial enzymes, a mechanism consistent with the lipophilic nature of the hexane-extracted constituents, though the precise bacterial targets have not been elucidated for these specific compounds. By analogy with related Buddleja species, class-level secondary metabolites such as verbascoside (a phenylethanoid glycoside) and buddledin A (an iridoid-related compound) may further modulate arachidonic acid cascades by inhibiting COX and 5-LOX enzymes, thereby reducing synthesis of prostaglandins and leukotrienes that mediate pain, bronchospasm, and gastrointestinal inflammation. The probable dione derivative (Compound 1) inhibits NF-κB at IC50 11.25–11.34 µM and may represent a structurally distinct pharmacophore within the extract that contributes to the overall [anti-inflammatory](/ingredients/condition/inflammation) effect through partially overlapping or complementary molecular interactions.

## Clinical Summary

No clinical trials of any phase have been conducted on Buddleja coriacea or its isolated constituents in human participants. The entirety of quantitative pharmacological data derives from in vitro antibacterial disk-diffusion and broth microdilution assays, and cell-based [NF-κB](/ingredients/condition/inflammation) reporter assays, which, while showing statistically significant results (p < 0.001 versus controls), cannot be translated into human efficacy or safety conclusions without pharmacokinetic, toxicological, and clinical investigation. Related Buddleja species have been referenced in animal models for COX-2 inhibition at doses approximating 3 g/kg body weight in hydroalcoholic extract form, but neither sample sizes nor effect sizes were specified for B. coriacea in these references, and interspecies dose extrapolation is not scientifically appropriate here. Confidence in any clinical benefit of kunuka remains very low by evidence-based medicine standards, and its use is currently supported only by traditional knowledge and preliminary in vitro data.

## Nutritional Profile

No formal nutritional analysis (proximate composition, micronutrient content, caloric value) has been published for Buddleja coriacea leaves. Phytochemical investigation has been limited to the identification of three bioactive compounds via NMR and mass spectrometry from hexane extracts—one probable dione derivative and two uncharacterized isolates—with no concentrations expressed per gram of dry plant material. By extrapolation from related Buddleja species, the genus is known to contain phenylethanoid glycosides (notably verbascoside), iridoid glycosides (including buddledin A), flavonoids (buddlenoid B, luteolin, apigenin), and carotenoid-related compounds (crocetin monogentibiosyl ester); whether these are present in B. coriacea leaves at pharmacologically relevant concentrations has not been established through direct phytochemical profiling. Bioavailability of the key lipophilic compounds (concentrated in the hexane subextract) would be expected to be influenced by food-matrix interactions, lipid co-ingestion, and first-pass hepatic [metabolism](/ingredients/condition/weight-management), but no human pharmacokinetic data exist to characterize absorption, distribution, metabolism, or excretion for any B. coriacea constituent.

## Dosage & Preparation

- **Traditional Leaf Infusion (Tea)**: Dried or fresh leaves are steeped in boiling water for 10–15 minutes; typical Quechua preparation uses approximately 5–10 g of dried leaf material per 250 mL of water, consumed 1–3 times daily for respiratory or digestive symptoms—no clinical dose-finding studies exist to confirm or refute this range.
- **Poultice (Topical Traditional Use)**: Fresh leaves are macerated and applied directly to inflamed or irritated skin areas in some Andean folk practices; no standardized preparation protocol or concentration data are available.
- **Hexane Extract (Research Use Only)**: Laboratory studies employed hexane subextracts and column chromatography fractions (F1–F4) at concentrations of 30–35 µg/mL in antibacterial assays and at µM-level purified compound concentrations for [NF-κB](/ingredients/condition/inflammation) inhibition; these are not formulated products and have no established human dose equivalent.
- **Hydroalcoholic Extract (Genus-Level Reference)**: Related Buddleja species have been studied at approximately 3 g/kg body weight in animal models using hydroalcoholic (ethanol/water) extracts; this datum is referenced only as contextual genus-level information and should not be used as a dosing guideline for B. coriacea in humans.
- **Standardized Supplement**: No commercially standardized B. coriacea supplement exists as of available records; no standardization percentage for any marker compound has been established or validated.

## Safety & Drug Interactions

The safety profile of Buddleja coriacea is essentially uncharacterized: no LD50 values, no-observed-adverse-effect levels (NOAELs), chronic toxicity data, or human adverse event reports have been published for this species or its isolated compounds. The in vitro fractionation study noted that the most bioactive fractions (F1, F3, F4) exhibited lower cytotoxicity relative to other fractions in cell-based assays, which is a preliminary and insufficient basis for concluding human safety. No drug interaction data exist; however, the potent NF-κB inhibitory activity of isolated compounds (IC50 0.15 µM for Compound 2) raises theoretical concerns about additive immunosuppressive effects if co-administered with corticosteroids, NSAIDs, biological [immunomodulat](/ingredients/condition/immune-support)ors, or other NF-κB pathway inhibitors, warranting caution until interaction studies are conducted. Use during pregnancy and lactation cannot be advised given the complete absence of reproductive toxicology data, and individuals with autoimmune conditions, those on anticoagulant or [anti-inflammatory](/ingredients/condition/inflammation) drug regimens, or those scheduled for surgery should avoid this herb until an adequate safety database is established.

## Scientific Research

The available scientific literature on B. coriacea is extremely limited and consists almost entirely of a single peer-reviewed in vitro study characterizing the antibacterial and [NF-κB](/ingredients/condition/inflammation) inhibitory properties of leaf extracts, subextracts, and isolated fractions; no sample sizes from human or animal cohorts were reported for B. coriacea specifically, and the research has not progressed beyond cell-based and microbial assays. Genus-level evidence from other Buddleja species (including studies on buddledin A for COX/5-LOX inhibition and computational docking studies on verbascoside and buddlenoid B) provides supportive mechanistic context, but these data cannot be directly extrapolated to B. coriacea without species-specific phytochemical confirmation. No randomized controlled trials, observational human studies, pharmacokinetic studies, or standardized extract formulations have been published for this species as of the available research record, placing it firmly in the preliminary preclinical evidence tier. The overall evidentiary base is insufficient to support therapeutic claims or dosage recommendations for human use, and any current applications remain grounded in traditional ethnobotanical practice rather than clinical validation.

## Historical & Cultural Context

Buddleja coriacea holds a significant place in the traditional healing systems of Quechua-speaking communities throughout the high Andes of Peru and Bolivia, where it is known by the local name 'kunuka' or related vernacular terms and has been used for generations to treat respiratory complaints (coughs, bronchitis, altitude-related breathing difficulties) and gastrointestinal disorders including in[digestion](/ingredients/condition/gut-health) and abdominal pain. The plant's resilience in extreme high-altitude environments likely contributed to its cultural status as a potent medicinal herb, with healers (curanderos and traditional midwives) preparing leaf decoctions and infusions as primary remedies in communities where access to pharmaceutical medicine has historically been limited. Within the broader Buddleja genus, multiple species carry distinct traditional medicine legacies: B. officinalis is used in traditional Chinese medicine for ocular and [anti-inflammatory](/ingredients/condition/inflammation) indications, and B. davidii (butterfly bush) has been referenced in European herbal traditions, demonstrating the genus's cross-cultural pharmacological relevance. The specific ethnobotanical documentation for B. coriacea remains sparse in the peer-reviewed literature, and systematic recording of Quechua healing practices involving this species represents an important gap in both ethnopharmacological and conservation research.

## Synergistic Combinations

No synergy studies have been conducted on B. coriacea in combination with other botanical or pharmaceutical agents. By analogy with the broader Buddleja genus and Andean ethnobotanical traditions, kunuka is sometimes combined with other high-altitude respiratory herbs such as muña (Minthostachys mollis) or eucalyptus in traditional infusion blends, where complementary volatile oil bronchodilatory activity (from muña) and NF-κB inhibitory action (from kunuka) may theoretically act on overlapping [inflammatory](/ingredients/condition/inflammation) and bronchospastic pathways. The combination of NF-κB inhibition (via kunuka's isolated compounds) with COX/LOX dual inhibition (as seen with buddledin A in related species) suggests a potential mechanistic rationale for pairing B. coriacea with omega-3 fatty acids or boswellic acids to achieve broader eicosanoid pathway modulation, though this remains entirely speculative without experimental confirmation.

## Frequently Asked Questions

### What is kunuka (Buddleja coriacea) used for traditionally?

In Quechua traditional medicine of the high Andes, kunuka leaves are prepared as infusions and decoctions to treat respiratory complaints such as cough and bronchial congestion, as well as digestive issues including abdominal pain and indigestion. These uses have not been validated in clinical trials, but the plant's in vitro NF-κB inhibitory activity provides a plausible mechanistic basis for its anti-inflammatory reputation.

### What bioactive compounds are found in Buddleja coriacea?

Three compounds have been isolated from B. coriacea leaf hexane extracts and characterized by NMR and mass spectrometry: a probable dione derivative (Compound 1) and two additional isolates (Compounds 2 and 3). Compound 2 is the most potent, inhibiting NF-κB with an IC50 of 0.15–0.16 µM and exhibiting antibacterial activity with a MIC of 0.17–0.19 µM, both values substantially more potent than standard reference drugs used in the same assays.

### Is there clinical trial evidence supporting kunuka supplementation?

No human clinical trials have been conducted on Buddleja coriacea or any of its isolated compounds. All available pharmacological data come from in vitro antibacterial and cell-based NF-κB inhibition assays; without pharmacokinetic, toxicological, and randomized controlled trial data, no evidence-based therapeutic claims can be made for this herb in human health.

### What is the safe dose of kunuka and are there known side effects?

No established safe dose, LD50, or standardized human dose exists for B. coriacea. While the most bioactive in vitro fractions showed relatively lower cytotoxicity compared to other fractions in the same study, this is insufficient to define a safe human dose, and no adverse event reports or drug interaction data have been published. Until formal toxicological studies are completed, caution is warranted, particularly for pregnant women and those on immunosuppressive or anti-inflammatory medications.

### How does kunuka compare to other Buddleja species in terms of medicinal properties?

Buddleja coriacea's isolated compounds demonstrated NF-κB inhibition more potent than the positive control celastrol and antibacterial activity exceeding ofloxacin in vitro, suggesting competitive potency within the genus. Related species like B. officinalis contain verbascoside and buddledin A (COX IC50 13.7 µM; 5-LOX IC50 50.4 µM), while B. coriacea's specific phytochemical profile has only been partially characterized, making direct comparative conclusions premature without full phytochemical fingerprinting of B. coriacea.

### How does kunuka's anti-inflammatory potency compare to other natural compounds?

Kunuka (Buddleja coriacea) contains compounds that inhibit NF-κB with IC50 values as low as 0.15–0.16 µM, making it significantly more potent than celastrol (IC50 7.96 µM), a well-established anti-inflammatory reference compound. This superior potency at the molecular level suggests kunuka may offer stronger anti-inflammatory effects compared to many other herbal alternatives. However, superior test-tube potency does not automatically translate to better real-world efficacy, which requires human clinical validation.

### What extraction method produces the most bioactive form of kunuka for anti-inflammatory benefits?

Research indicates that leaf extracts of Buddleja coriacea contain the anti-inflammatory compounds, with specific isolation protocols demonstrating significant NF-κB inhibition in laboratory studies. The most bioactive fractions appear to be solvent-extracted forms that concentrate the active constituents, though optimal extraction and preparation methods for supplemental use have not been definitively established in human studies. Standardization of kunuka extracts to specific compound concentrations would improve consistency and efficacy of supplemental products.

### Can kunuka supplementation support immune function through its antibacterial properties?

Kunuka (Buddleja coriacea) demonstrates antibacterial activity in laboratory studies, with certain hexane-extracted fractions showing promising antimicrobial effects against various bacterial species. While these in vitro results are encouraging, the clinical relevance to immune support requires human studies examining whether these antibacterial compounds reach effective concentrations in the body and can meaningfully reduce bacterial burden or infection risk. Current evidence remains preliminary, and kunuka should not be relied upon as a substitute for conventional antibiotics or proven immune-support interventions.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*